Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease

Abstract

Correction: Alz Res Therapy 16, 105 (2024)

https://doi.org/10.1186/s13195-024-01441-8

Following publication of the original article [1], several typographical errors were observed:

• In Table 2, recurrent ARIA-E for ApoE carriers should be 3.8% (not 11.7%).

• In Table 2, there were several incorrect indentations for several rows (old and updated versions of Table 2 are presented below).

• There are two places on page 6 where ‘ARIA-E’ should be ‘ARIA’.

• In Table 5, the asterisk in right column should be a superscript ‘1’. The footnote should have an end parenthesis at end of the footnote sentence below the table.

Moreover, Supplementary material 1 (.docx) has been replaced with its pdf version with modification in Table S4 - ID21 (the participant should be “male” instead of “female”).

The old version of Table 2:

Table 2 Adverse events and ARIA in Clarity Core and Core + OLE

Full size table

The updated version of Table 2:

Table 2 Adverse events and ARIA in Clarity Core and Core + OLE

Full size table

The original article [1] has been updated.

1. Honig LS, Sabbagh MN, van Dyck CH, et al. Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease. Alz Res Therapy. 2024;16:105. https://doi.org/10.1186/s13195-024-01441-8

   Article CAS Google Scholar

Download references

Authors and Affiliations

1. Columbia University Irving Medical Center, NYS Center of Excellence for Alzheimer’s Disease, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, Gertrude H. Sergievsky Center (PH19), & Department of Neurology, Columbia University Vagelos College of Physicians & Surgeons, 630 West 168th Street (P&S UNIT 16), New York, NY, 10032-3795, USA

   Lawrence S. Honig

2. Barrow Neurological Institute, Phoenix, AZ, 85013, USA

   Marwan N. Sabbagh

3. Yale School of Medicine, New Haven, CT, USA

   Christopher H. van Dyck

4. Brigham and Women’s Hospital, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

   Reisa A. Sperling

5. Eisai Inc., Nutley, NJ, USA

   Steven Hersch, Andre Matta, Michio Kanekiyo, David Li, Shobha Dhadda, Michael Irizarry & Lynn Kramer

6. Eisai Co., Ltd, Hatfield, UK

   Luigi Giorgi & Michelle Gee

7. Clario, Philadelphia, PA, USA

   Derk Purcell

Authors

1. Lawrence S. HonigView author publications

   You can also search for this author in PubMed Google Scholar

2. Marwan N. SabbaghView author publications

   You can also search for this author in PubMed Google Scholar

3. Christopher H. van DyckView author publications

   You can also search for this author in PubMed Google Scholar

4. Reisa A. SperlingView author publications

   You can also search for this author in PubMed Google Scholar

5. Steven HerschView author publications

   You can also search for this author in PubMed Google Scholar

6. Andre MattaView author publications

   You can also search for this author in PubMed Google Scholar

7. Luigi GiorgiView author publications

   You can also search for this author in PubMed Google Scholar

8. Michelle GeeView author publications

   You can also search for this author in PubMed Google Scholar

9. Michio KanekiyoView author publications

   You can also search for this author in PubMed Google Scholar

10. David LiView author publications

    You can also search for this author in PubMed Google Scholar

11. Derk PurcellView author publications

    You can also search for this author in PubMed Google Scholar

12. Shobha DhaddaView author publications

    You can also search for this author in PubMed Google Scholar

13. Michael IrizarryView author publications

    You can also search for this author in PubMed Google Scholar

14. Lynn KramerView author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lawrence S. Honig.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://doi.org/10.1186/s13195-024-01441-8.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

Cite this article

Honig, L.S., Sabbagh, M.N., van Dyck, C.H. et al. Correction: Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease. Alz Res Therapy 16, 159 (2024). https://doi.org/10.1186/s13195-024-01507-7

Download citation

• Published: 10 July 2024

• DOI: https://doi.org/10.1186/s13195-024-01507-7

Share this article

Anyone you share the following link with will be able to read this content:

Get shareable link

Sorry, a shareable link is not currently available for this article.

Copy to clipboard

Provided by the Springer Nature SharedIt content-sharing initiative